Research programme: farnesyl transferase inhibitors - Abbott Laboratories

Drug Profile

Research programme: farnesyl transferase inhibitors - Abbott Laboratories

Alternative Names: A 409100; ABT 100; Farnesyl transferase inhibitors research programme - Abbott

Latest Information Update: 23 Jan 2013

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Class Imidazoles
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Transplant rejection

Most Recent Events

  • 20 May 2004 Preclinical trials in Transplant rejection in USA (unspecified route)
  • 20 May 2004 Data presented at the American Transplant Congress 2004 (ATC-2004) have been added to the Transplant rejection pharmacodynamics section
  • 22 Jul 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top